Our Research
Degenerative disorders of the brain, including Parkinson’s, are becoming more common in our ageing population and represent an urgent unmet medical need. Our research is structured around three overlapping themes.
Read more
About Us
The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford. The OPDC was established in February 2010 and brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Upcoming Seminars
Latest publications
-
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
Vijiaratnam N. et al, (2025), Lancet, 405, 627 - 636
-
USP30 inhibition improves mitochondrial health through both PINK1-dependent and independent mechanisms
Williamson MG. et al, (2025)
-
Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
Sauerbier A. et al, (2024), npj Parkinson's Disease, 10
-
A worldwide study of subcortical shape as a marker for clinical staging in Parkinson's disease.
Laansma MA. et al, (2024), NPJ Parkinsons Dis, 10
-
Impaired striatal glutathione-ascorbate metabolism induces transient dopamine increase and motor dysfunction.
Malik MY. et al, (2024), Nat Metab
-
Beta bursts in the parkinsonian cortico-basal ganglia network form spatially discrete ensembles.
Grennan I. et al, (2024), Neurobiol Dis, 201